Skip to main content
BioPlus Co., Ltd logo

BioPlus Co., Ltd — Investor Relations & Filings

Ticker · 099430 ISIN · KR7099430001 KO Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2022-03-16 Proxy Solicitation & In…
Country KR South Korea
Listing KO 099430

About BioPlus Co., Ltd

https://ubioplus.com/

BioPlus Co., Ltd. is a company that researches, develops, and manufactures biomaterials, with a primary focus on hyaluronic acid (HA) applications. The company's core competency is its proprietary MDM® Technology, which is used to create a diverse product portfolio for the beauty and healthcare industries. Key products include a range of dermal and body fillers, skin boosters, anti-adhesion agents, biomaterial breast implants, and artificial cartilage. The company aims to provide bio-therapy solutions by addressing fundamental cellular-level issues through its advanced technologies.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for BioPlus Co., Ltd. It details the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits) for the 19th Annual General Meeting. It also includes management's business report and governance information as required by law for shareholder review. This document is a standard proxy statement/notice for an upcoming shareholder meeting.
2022-03-16 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'Bioplus'. It outlines the date, location, and specific agenda items (proposals) to be voted on, including financial statement approval, board appointments, and remuneration limits. This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of upcoming meeting details and agenda items.
2022-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies' meetings, citing audit schedules and reporting obligations. Since this is a specific regulatory disclosure required by the exchange and does not fit into the other categories like AGM-R (presentation materials) or PSI (proxy solicitation), it is classified as a general regulatory filing.
2022-03-14 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status via Trust Agreement' (신탁계약등에의한취득상황보고서) filed by BioPlus Co., Ltd. with the Financial Supervisory Service. It details the company's purchase of its own shares through a trust contract with Korea Investment & Securities. This type of filing, which reports the company's activity in buying back its own shares, falls under the 'Transaction in Own Shares' category.
2022-03-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Bioplus) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides the initial announcement of financial results and key highlights rather than a full annual report or a transcript, it falls under the Earnings Release category. FY 2021
2022-02-16 Korean
신탁계약에의한취득상황보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on Acquisition Status by Trust Agreement' (신탁계약등에의한취득상황보고서) filed by BioPlus Co., Ltd. to the Financial Supervisory Service. It details the company's purchase of its own shares through a trust contract with Korea Investment & Securities. This falls under the category of a company reporting the buyback of its own shares, which is classified as 'Transaction in Own Shares' (POS).
2022-01-17 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.